Treatment of Esophageal Candidiasis in Patients with Prolonged QTc Interval
Understanding the Risk of QTc Prolongation with Antifungals
- QTc interval prolongation is a key drug safety parameter, with significant prolongation associated with potentially life-threatening ventricular arrhythmias such as torsade de pointes 1
- While QT interval prolongation is common in cancer patients and other populations, clinical events are rare but potentially lethal 1
- Echinocandins appear to be safe with minimal side effects and no significant QTc prolongation concerns 2
Treatment Algorithm for Esophageal Candidiasis with Prolonged QTc
- The Infectious Diseases Society of America recommends using an echinocandin for 14-21 days 2
- The European Society of Clinical Microbiology and Infectious Diseases suggests micafungin 150 mg IV daily, caspofungin 70 mg IV loading dose followed by 50 mg IV daily, or anidulafungin 200 mg IV daily 2
Monitoring During Treatment
- The American Heart Association recommends ECG monitoring at baseline and periodically during treatment 1, 6
- The European Heart Journal suggests correcting any electrolyte abnormalities, particularly hypokalemia and hypomagnesemia, which can exacerbate QTc prolongation 1, 6
- The European Society of Cardiology recommends avoiding concomitant QT-prolonging medications whenever possible 6
Management of Fluconazole-Refractory Disease
- The Infectious Diseases Society of America recommends echinocandins as the treatment of choice for fluconazole-refractory disease in patients with prolonged QTc 2
- The Clinical Infectious Diseases journal suggests amphotericin B deoxycholate 0.3-0.7 mg/kg daily for 21 days as an alternative option 2
Prevention of Recurrence
- The Centers for Disease Control and Prevention recommends addressing underlying immunodeficiency if possible (e.g., antiretroviral therapy for HIV-infected patients) 2, 7
- The Infectious Diseases Society of America suggests considering intermittent echinocandin therapy rather than chronic azole therapy for patients with recurrent esophageal candidiasis requiring suppressive therapy 2